AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18419878
Drug: budesonide DPI-B
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: budesonide DPI-B 180 microg once daily (total daily dose 180 microg)
Trial: 18419878
Drug: budesonide DPI-B
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: budesonide DPI-B 360 microg twice-daily
Trial: 18419878
Drug: budesonide DPI-A
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: budesonide DPI-A 400 microg twice-daily
Trial: 18419878
Drug: budesonide DPI-B
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: budesonide DPI-B 180 microg once daily
Trial: 18419878
Drug: budesonide DPI-A
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: budesonide DPI-A 200 microg once daily
Trial: 16965691
Drug: Parenteral nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutrition with alanyl-glutamine dipeptide
Trial: 12856155
Drug: 0.9 mg
RxNorm normalized name: estradiol 0.9 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9 mg recombinant human TSH (rhTSH) followed by 2 mCi (74 MBq) iodine-131
Trial: 12856155
Drug: 2 mCi
RxNorm normalized name: Iobenguane I 123 2 MCI/1 ML Intravenous Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mCi (74 MBq) iodine-131 administered after stopping thyroid hormones to become hypothyroid
Trial: 1328365
Drug: Dietary treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary treatment based upon weight reduction and sodium restriction
Trial: 3870293
Drug: Aclatonium napadisilate
RxNorm normalized name: mebhydrolin napadisylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aclatonium napadisilate (TM-723) at a dose of 50 mg
Trial: 3870293
Drug: Prostaglandine F2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostaglandine F2 alpha (PGF2 alpha) at a dose of 2 mg
Trial: 30291013
Drug: Placebo (matched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (matched volume, subcutaneous injection once a week)
Trial: 24607553
Drug: etanercept (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etanercept (0.4 mg/kg twice weekly × 4 weeks)
Trial: 9431859
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg irbesartan once a day
Trial: 8237833
Drug: Conventional antiarrhythmic
RxNorm normalized name: ANTIARRHYTHMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional antiarrhythmic therapy
Trial: 3800090
Drug: Topical 1%
RxNorm normalized name: fluoride topical 1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 1% povidone-iodine (Betadine)
Trial: 20860413
Drug: Colesevelam (3.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colesevelam (3.75 g/day)
Trial: 17999256
Drug: Atypical antipsychotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atypical antipsychotic drugs (various types)
Trial: 31571445
Drug: Teneligliptin 20
RxNorm normalized name: teneligliptin
DrugBank: Teneligliptin (DB11950)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Teneligliptin 20 mg once daily for 12 weeks
Trial: 24344941
Drug: Sitagliptin 100
RxNorm normalized name: SITagliptin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 100 mg once daily for 12 weeks
Trial: 28255099
Drug: NT‐proBNP cut-off
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NT‐proBNP cut-off of ≥125 ng/L
Trial: 14962527
Drug: Best treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best treatment without hormones (non-HRT)
Trial: 20056931
Drug: Intravenous tissue
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous tissue plasminogen activator (tPA)
Trial: 8391063
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin A (retinol palmitate, orally 300,000 IU daily for 12 months)
Trial: 15513568
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin A
Trial: 27593794
Drug: Ultrasound-guided caudal
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided caudal epidural steroid injection
Trial: 19924670
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg oral prednisolone for 10 days
Trial: 16380544
Drug: 1.6 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.6 mg/d riboflavin for 12 weeks
Trial: 1354225
Drug: Cetirizine, 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine, 15 mg twice a day (6 patients)
Trial: 6238133
Drug: DDAVP (vasopressin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DDAVP (vasopressin derivative) administered for 10 days, 40 micrograms per day
Trial: 26453645
Drug: EBV IgG
RxNorm normalized name: EBV-CTL
DrugBank: Tabelecleucel (DB17072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EBV IgG antibody levels
Trial: 26453645
Drug: Cotinine levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cotinine levels >25 ng/mL
Trial: 23350967
Drug: ICD only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICD only treatment
Trial: 21263058
Drug: Lidocaine 2%
RxNorm normalized name: LIDOCAINE 2% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 2% (1 mg/kg) and IV Fentanyl (1 μg/kg)
Trial: 11895966
Drug: WRSS1 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WRSS1 vaccine (3 x 10(3) CFU)
Trial: 11895966
Drug: WRSS1 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WRSS1 vaccine (3 x 10(4) CFU)
Trial: 11895966
Drug: WRSS1 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WRSS1 vaccine (3 x 10(5) CFU)
Trial: 11895966
Drug: WRSS1 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WRSS1 vaccine (3 x 10(6) CFU)
Trial: 11895966
Drug: WRSS1 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WRSS1 vaccine (all groups)
Trial: 7872318
Drug: Higher dialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dialysis efficacy (Kt/V urea and nPCR of 1.28 and 1.22 g/kg/d)
Trial: 645142
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg glibenclamide daily
Trial: 645142
Drug: Usual diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual diet therapy
Trial: 29578103
Drug: Bronchodilator (BD;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bronchodilator (BD; ipratropium 0.5mg + salbutamol 2.5 mg)
Trial: 26514352
Drug: Oral anticoagulation
RxNorm normalized name: monitoring agent for oral anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulation with dabigatran after pulmonary vein isolation for atrial fibrillation
Trial: 20601671
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no EPO treatment)
Trial: 11401877
Drug: Glycophosphopeptical (Inmunoferón)
RxNorm normalized name: glicofosfopeptical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycophosphopeptical (Inmunoferón) at oral doses of 3 g/d for 90 days
Trial: 9184521
Drug: Injection drug
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection drug use history among homeless men in Baltimore
Trial: 9184521
Drug: Injection drug
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection drug use history among homeless men in Boston
Trial: 9184521
Drug: Injection drug
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection drug use history among homeless women in Baltimore
Trial: 9184521
Drug: Injection drug
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection drug use history among homeless women in Boston
Trial: 11685055
Drug: Topical autologous
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical autologous serum as a tear substitute
Trial: 11685055
Drug: Unpreserved normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unpreserved normal saline solution as a placebo
Trial: 9742917
Drug: Surgery plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery plus early postoperative intraperitoneal chemotherapy (mitomycin C on day 1 and 5-fluorouracil on days 2-5)
Trial: 9742917
Drug: Surgery plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery plus early postoperative intraperitoneal chemotherapy
Trial: 7799589
Drug: Endolymphatic injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endolymphatic injection of gentamycin and myelopid
Trial: 23325582
Drug: Panitumumab treatment
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Panitumumab treatment
Trial: 21508863
Drug: Evening dose
RxNorm normalized name: Jornay PM, (evening dose) 60 mg/24 hr oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evening dose of hydroxyzine 50 mg
Trial: 21508863
Drug: Morning dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning dose of hydroxyzine 50 mg
Trial: 18225471
Drug: No-treatment control
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-treatment control group with nurse arm and one in-home session following trial completion at 6-months
Trial: 14985185
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein isolate (WPI) supplementation (0.8 or 1.6 g/kg body mass)
Trial: 29114095
Drug: Bridging therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bridging therapy (intravenous thrombolysis plus MT)
Trial: 23922184
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with non‐ablative fractional laser and optimized intense pulsed light (Group A)
Trial: 17883994
Drug: Nonpharmacologic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonpharmacologic therapy including cardiac resynchronization therapy, left ventricular assist devices, and cardiac rehabilitation
Trial: 17883994
Drug: Interventions aimed
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interventions aimed at treatment of acute HF syndromes
Trial: 15248853
Drug: Anti-IgE treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-IgE treatment
Trial: 10396235
Drug: Microimmunofluorescence test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microimmunofluorescence test (MIF) for IgG, IgM, and IgA antibodies to C pneumoniae
Trial: 6338993
Drug: 2% lignocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lignocaine gel with St Mark's Hospital anal dilator
Trial: 31799782
Drug: Liraglutide (1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide (1.8 mg/day)
Trial: 21392601
Drug: Local infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local infusion of abciximab after aspiration with a 6F Export Aspiration Catheter
Trial: 21392601
Drug: Local infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local infusion of abciximab and no aspiration
Trial: 21392601
Drug: No local
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No local infusion of abciximab and aspiration with a 6F Export Aspiration Catheter
Trial: 21392601
Drug: No local
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No local infusion of abciximab and no aspiration
Trial: 22216509
Drug: Metoprolol (75-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (75-300 mg) in combination with chlorthalidone
Trial: 22216509
Drug: Placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in combination with chlorthalidone
Trial: 29709447
Drug: Quadrivalent Inactivated
RxNorm normalized name: Fluarix Quadrivalent 2018-2019
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent Inactivated Vaccine (QIV)
Trial: 14577025
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline solution (Placebo)
Trial: 9356529
Drug: Black tea
RxNorm normalized name: black tea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Black tea (900 mL/d)
Trial: 9356529
Drug: Control (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (900 mL mineral water/d)
Trial: 155891
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ipratropium and salbutamol
Trial: 25622681
Drug: Intranasal lignocaine/phenylephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal lignocaine/phenylephrine
Trial: 16481389
Drug: Topotecan at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topotecan at a starting dose of 1.25 mg.m(‐2) with individual dose adjustment, administered intravenously on days 1‐5, every 21 days, for up to six courses.
Trial: 8263310
Drug: l-fenfluramine
RxNorm normalized name: DL-Fenfluramine
DrugBank: Fenfluramine (DB00574)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-fenfluramine
Trial: 3906545
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment plus intravenous piperacillin
Trial: 3906545
Drug: Standard antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antibiotic treatment (flucloxacillin plus tobramycin)
Trial: 17637608
Drug: Drug-naive controls
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-naive controls
Trial: 16177613
Drug: Trained limb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trained limb agonist EMG activation
Trial: 12680882
Drug: Captopril 3
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril 3 x 25 mg day-1
Trial: 10535657
Drug: ST (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ST (standard treatment)
Trial: 8735864
Drug: Thiorphan (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiorphan (1.25 mg/mL, 0.5 mL)
Trial: 21840137
Drug: Weekly cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly cisplatin 40 mg/m(2), six cycles
Trial: 21840137
Drug: Triweekly cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triweekly cisplatin 75 mg/m(2) every 3 weeks, three cycles
Trial: 15608761
Drug: Curamed colostrum
RxNorm normalized name: COLOSTRUM
DrugBank: Human colostrum (DB19286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curamed colostrum tablets
Trial: 3541824
Drug: Metoprolol, 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol, 150 mg daily
Trial: 3541824
Drug: Atenolol, 100
RxNorm normalized name: Atenolol, 100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol, 100 mg daily
Trial: 3541824
Drug: Drug-free control
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-free control day
Trial: 24052631
Drug: Oral paricalcitol
RxNorm normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral paricalcitol (1 μg one time daily)
Trial: 20816187
Drug: LABA monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LABA monotherapy
Trial: 15851891
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg lidocaine infused over 30 min
Trial: 10562779
Drug: Nebulized lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulized lidocaine (4% solution, 4 ml)
Trial: 475943
Drug: Dexamphetamine 10
RxNorm normalized name: Dexamphetamine
DrugBank: Dextroamphetamine (DB01576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamphetamine 10 mg
Trial: 9337378
Drug: Bupropion 100
RxNorm normalized name: buPROPion 100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion 100 mg
Trial: 6405773
Drug: Bupropion 200
RxNorm normalized name: buPROPion 200 mg/12 hours oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion 200 mg
Trial: 3397523
Drug: Nomifensine 100
RxNorm normalized name: nomifensine
DrugBank: Nomifensine (DB04821)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nomifensine 100 mg
Trial: 30428122
Drug: Transcutaneous supraorbital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcutaneous supraorbital neurostimulation (tSNS) for 20 minutes daily for 3 months
Trial: 25555562
Drug: Polydextrose (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polydextrose (15 g)
Trial: 23303421
Drug: Continuation ECT
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuation ECT with pharmacotherapy
Trial: 19665538
Drug: 50 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/kg body weight of freeze dried Momordica charantia (MC50)
Trial: 19665538
Drug: 100 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/kg body weight of freeze dried Momordica charantia (MC100)
Trial: 12784050
Drug: Polymyxin B-immobilized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polymyxin B-immobilized fiber (PMX) treatment
Trial: 26383592
Drug: Topical 8-methoxypsoralen
RxNorm normalized name: 8-methoxypsoralen
DrugBank: Methoxsalen (DB00553)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical 8-methoxypsoralen (8-MOP) 2.6 mg L(-1)
Trial: 24524806
Drug: Lixisenatide 5
RxNorm normalized name: LIXISENATIDE 50/100MCG/MLX3ML START KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lixisenatide 5 and 10 µg single dose; 5 to 30 µg once (QD) or twice daily (BID) for 5-6 weeks
Trial: 22380715
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TXA) administered within one hour of injury
Trial: 22380715
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TXA) administered within three hours of injury
Trial: 17378785
Drug: Priming dose
RxNorm normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Priming dose of propofol 10 mg/ml
Trial: 17378785
Drug: Sodium chloride
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium chloride 9.0 mg/ml
Trial: 12094125
Drug: CHO/PRO (8.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO/PRO (8.4 Mj x day(‐1) or 2010 kcal, 356 g carbohydrate, 106 g protein)
Trial: 12094125
Drug: CHO (isocaloric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO (isocaloric carbohydrate supplement)
Trial: 10221439
Drug: BUD 1600
RxNorm normalized name: Clove buds
DrugBank: Clove (DB10672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BUD 1600 microg inhaled into the lungs
Trial: 10221439
Drug: BUD (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BUD (200 and 800 microg) and FP (200 and 800 microg) administered in the nose
Trial: 10221439
Drug: FP (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FP (1500 microg) inhaled into the lungs
Trial: 2331054
Drug: 0.005 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.005 mg/kg fentanyl prior to intubation
Trial: 31409556
Drug: Colchicine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine (1.5 mg PO)
Trial: 23722418
Drug: Nicorandil (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicorandil (2 mg)
Trial: 23722418
Drug: Nitroglycerin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin (250 μg)
Trial: 21479243
Drug: Physical activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical activity promotion by general practitioners (repeat prescription subgroup)
Trial: 19451428
Drug: Melphalan and
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Melphalan and prednisone plus thalidomide (100 mg/d for 72 weeks)
Trial: 16939514
Drug: Low-dose cyclosporine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cyclosporine A (CsA)
Trial: 10202164
Drug: Pelvic radiation
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelvic radiation and concurrent chemotherapy with fluorouracil and cisplatin (45 Gy of radiation to the pelvis plus two cycles of chemotherapy).